Overexpression of dihydrofolate reductase is a factor of poor survival in acute lymphoblastic leukemia

Autor:	Marco Antonio Leyva-Vázquez, Jorge Organista-Nava, Yazmín Gómez-Gómez, Ana Bertha Rivera-Ramírez, Mónica Virginia Saavedra-Herrera, Berenice Illades-Aguiar
Jazyk:	angličtina
Rok vydání:	2018
Předmět:	0301 basic medicine Cancer Research acute lymphoblastic leukemia Biology Reductase survival Andrology 03 medical and health sciences 0302 clinical medicine dihydrofolate reductase White blood cell Dihydrofolate reductase parasitic diseases medicine heterocyclic compounds Oncogene Articles Cell cycle medicine.disease Molecular medicine Leukemia 030104 developmental biology medicine.anatomical_structure Oncology 030220 oncology & carcinogenesis biology.protein Methotrexate prognosis medicine.drug
Zdroj:	Oncology Letters
ISSN:	1792-1082 1792-1074
Popis:	Dihydrofolate reductase (DHFR) has an important function in DNA synthesis and is a target of methotrexate, which is a crucial treatment option for acute lymphoblastic leukemia (ALL). However, the number of studies conducted to date on DHFR expression in childhood ALL is limited. The aim of the present study was to determine whether the expression of DHFR is associated with survival in childhood ALL. The expression of DHFR in 96 children with ALL and 100 control individuals was determined using reverse transcription-quantitative polymerase chain reaction. The results of the present study demonstrated that the expression of DHFR mRNA in children with ALL was significantly increased (P
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::412ab90fcfbe8f85c4cba0cc4deeeeb7 http://europepmc.org/articles/PMC5950508 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.